Anavex 2-73 Slows Cognitive Decline in Alzheimer’s Patients, Phase 2 Extension Trial Shows

Anavex 2-73 Slows Cognitive Decline in Alzheimer’s Patients, Phase 2 Extension Trial Shows
Treatment with Anavex's investigational therapy Anavex 2-73 significantly reduces cognitive decline in people with Alzheimer’s disease and sustains their ability to perform daily activities, according to interim data from a Phase 2 extension study. Trial results were presented in a late-breaking oral presentation, titled “Longitudinal 148-Week Extension Study for ANAVEX®2-73 Phase 2a Alzheimer’s Disease Demonstrates Maintained Activities of Daily Living Score (ADCS-ADL) and Reduced Cognitive Decline (MMSE) for Patient Cohort on Higher Drug Concentration and Confirms Role of Patient Selection Biomarkers,” at the recent 
Subscribe or to access all post and page content.